| P/E (FY) | — | Sales (TTM) | €186,000 |
| Earnings (TTM) | -€5.8M | ROE | −170.92% |
| Net Margin | −3131.18% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Celyad Oncology SA is a biotechnology company centered on developing its intellectual property portfolio. Its assets include multiple foundational US patents covering TCR-deficient T cell compositions and broadly addressing allogeneic CAR T cell therapies. Previously named Celyad SA before adopting its current name in June 2020, the company was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
| Market Cap | — | Trading Days | 3290 |
| 52W High | 0.65 |
| 52W Low | 0.16 |
| % Off High | −55.54% |
| YTD | 70.00% | 1Y | −42.08% |
| 3Y | −45.27% | 5Y | −92.13% |
| 10Y | −98.70% | Since incept. (ann.) | −26.68% |
| Ann. Volatility (1Y) | 99.62% | Ann. Volatility (3Y) | 126.17% |
| Sharpe (1Y) | −0.11 | Sharpe (3Y) | 0.37 |
| Max Drawdown (1Y) | −66.33% | Max Drawdown (3Y) | −84.15% |
| Beta (3Y, vs SPY) | 0.14 |
No same-industry peers in the universe for CYAD.BR.
